Sara Shalin
Concepts (416)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 32 | 2024 | 532 | 8.340 |
Why?
| Skin Diseases | 7 | 2022 | 141 | 4.130 |
Why?
| Melanoma | 15 | 2021 | 313 | 3.320 |
Why?
| Dermatology | 8 | 2021 | 72 | 3.200 |
Why?
| Skin | 11 | 2021 | 469 | 2.480 |
Why?
| Sebaceous Gland Neoplasms | 5 | 2022 | 15 | 1.950 |
Why?
| Carcinoma, Basal Cell | 5 | 2018 | 44 | 1.880 |
Why?
| Immunohistochemistry | 17 | 2021 | 1089 | 1.840 |
Why?
| Staining and Labeling | 3 | 2021 | 106 | 1.710 |
Why?
| Adenocarcinoma, Sebaceous | 3 | 2022 | 6 | 1.690 |
Why?
| Nevus, Blue | 2 | 2021 | 13 | 1.470 |
Why?
| Melanocytes | 3 | 2021 | 39 | 1.460 |
Why?
| Biopsy | 17 | 2021 | 692 | 1.420 |
Why?
| Dermatitis | 2 | 2022 | 42 | 1.330 |
Why?
| Erythema Multiforme | 2 | 2020 | 12 | 1.270 |
Why?
| Humans | 79 | 2024 | 54284 | 1.230 |
Why?
| Vulvar Neoplasms | 3 | 2022 | 54 | 1.150 |
Why?
| Female | 44 | 2024 | 28441 | 1.110 |
Why?
| Nevus, Pigmented | 2 | 2016 | 37 | 1.080 |
Why?
| Herpes Simplex | 2 | 2022 | 24 | 1.060 |
Why?
| Middle Aged | 30 | 2022 | 13088 | 0.990 |
Why?
| Sweat Gland Neoplasms | 3 | 2024 | 24 | 0.980 |
Why?
| Aged, 80 and over | 17 | 2022 | 3431 | 0.970 |
Why?
| Nevus, Epithelioid and Spindle Cell | 3 | 2018 | 15 | 0.930 |
Why?
| Papillomavirus Infections | 2 | 2022 | 163 | 0.930 |
Why?
| Hyperoxaluria | 1 | 2022 | 5 | 0.900 |
Why?
| Hyperoxaluria, Primary | 1 | 2022 | 4 | 0.900 |
Why?
| Urolithiasis | 1 | 2022 | 6 | 0.890 |
Why?
| Graft vs Host Disease | 2 | 2020 | 83 | 0.890 |
Why?
| Pathology | 2 | 2020 | 43 | 0.870 |
Why?
| Epidermal Cyst | 1 | 2022 | 14 | 0.860 |
Why?
| Granuloma | 2 | 2020 | 45 | 0.860 |
Why?
| Adenoma | 2 | 2017 | 142 | 0.850 |
Why?
| Carcinoma in Situ | 1 | 2022 | 74 | 0.850 |
Why?
| Protein Kinases | 2 | 2016 | 89 | 0.830 |
Why?
| Muscle, Smooth | 1 | 2021 | 68 | 0.820 |
Why?
| Aged | 25 | 2022 | 10054 | 0.810 |
Why?
| Elastic Tissue | 2 | 2020 | 10 | 0.800 |
Why?
| Fungi | 1 | 2021 | 48 | 0.800 |
Why?
| Epidermodysplasia Verruciformis | 1 | 2020 | 2 | 0.790 |
Why?
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2020 | 2 | 0.780 |
Why?
| Artifacts | 1 | 2021 | 61 | 0.780 |
Why?
| Foreign Bodies | 1 | 2021 | 64 | 0.780 |
Why?
| Methenamine | 1 | 2020 | 2 | 0.770 |
Why?
| Periodic Acid-Schiff Reaction | 1 | 2020 | 2 | 0.770 |
Why?
| Histiocytoma, Benign Fibrous | 1 | 2020 | 17 | 0.770 |
Why?
| Diagnosis, Differential | 12 | 2022 | 1136 | 0.770 |
Why?
| Oncogene Proteins, Fusion | 2 | 2020 | 60 | 0.770 |
Why?
| Lichenoid Eruptions | 1 | 2020 | 4 | 0.770 |
Why?
| Vulvar Diseases | 1 | 2020 | 7 | 0.770 |
Why?
| Genitalia | 1 | 2020 | 15 | 0.750 |
Why?
| Lichen Sclerosus et Atrophicus | 1 | 2020 | 8 | 0.750 |
Why?
| Uterine Cervical Dysplasia | 1 | 2020 | 51 | 0.750 |
Why?
| Syphilis | 1 | 2020 | 25 | 0.750 |
Why?
| Kidney Failure, Chronic | 1 | 2022 | 231 | 0.750 |
Why?
| Lymphatic Metastasis | 2 | 2020 | 256 | 0.740 |
Why?
| Gynecology | 1 | 2020 | 50 | 0.740 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 76 | 0.720 |
Why?
| Pseudoxanthoma Elasticum | 1 | 2019 | 6 | 0.710 |
Why?
| Pathology, Surgical | 1 | 2019 | 27 | 0.690 |
Why?
| Adult | 21 | 2022 | 14207 | 0.670 |
Why?
| Pathology, Clinical | 4 | 2021 | 26 | 0.670 |
Why?
| Fibroma | 2 | 2020 | 41 | 0.670 |
Why?
| Telangiectasis | 1 | 2018 | 4 | 0.660 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.650 |
Why?
| Male | 30 | 2024 | 27334 | 0.630 |
Why?
| Carcinoma, Large Cell | 1 | 2017 | 17 | 0.630 |
Why?
| Neoplasms, Multiple Primary | 1 | 2018 | 45 | 0.630 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2017 | 27 | 0.620 |
Why?
| Carcinoma, Squamous Cell | 2 | 2024 | 384 | 0.620 |
Why?
| Hidrocystoma | 1 | 2017 | 5 | 0.620 |
Why?
| Apocrine Glands | 1 | 2017 | 5 | 0.620 |
Why?
| Calcium Oxalate | 1 | 2017 | 10 | 0.620 |
Why?
| Laryngeal Neoplasms | 1 | 2017 | 55 | 0.610 |
Why?
| Inflammation | 2 | 2020 | 674 | 0.580 |
Why?
| Tumor Suppressor Protein p53 | 3 | 2020 | 250 | 0.560 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 70 | 0.540 |
Why?
| Carcinoma, Merkel Cell | 2 | 2022 | 47 | 0.540 |
Why?
| Brain Neoplasms | 2 | 2020 | 284 | 0.540 |
Why?
| Sarcoptes scabiei | 1 | 2015 | 2 | 0.530 |
Why?
| Scabies | 1 | 2015 | 4 | 0.530 |
Why?
| Transcription Factors | 2 | 2021 | 622 | 0.530 |
Why?
| Genital Diseases, Male | 1 | 2015 | 20 | 0.520 |
Why?
| Lymphangioma | 1 | 2014 | 10 | 0.520 |
Why?
| Scrotum | 1 | 2015 | 34 | 0.510 |
Why?
| Histiocytosis, Sinus | 1 | 2015 | 17 | 0.510 |
Why?
| Arm | 1 | 2014 | 52 | 0.480 |
Why?
| Acanthoma | 1 | 2013 | 2 | 0.480 |
Why?
| Fibroadenoma | 1 | 2013 | 7 | 0.480 |
Why?
| Eccrine Glands | 1 | 2013 | 11 | 0.480 |
Why?
| Young Adult | 9 | 2022 | 4318 | 0.450 |
Why?
| Nuclear Proteins | 1 | 2014 | 252 | 0.440 |
Why?
| Leuprolide | 1 | 2012 | 2 | 0.440 |
Why?
| Mucinosis, Follicular | 1 | 2012 | 3 | 0.440 |
Why?
| Drug Eruptions | 1 | 2012 | 14 | 0.440 |
Why?
| Endometriosis | 1 | 2012 | 16 | 0.440 |
Why?
| Cicatrix | 1 | 2012 | 43 | 0.430 |
Why?
| Mycosis Fungoides | 1 | 2012 | 28 | 0.430 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2012 | 37 | 0.430 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2012 | 49 | 0.430 |
Why?
| Thrombosis | 1 | 2015 | 243 | 0.420 |
Why?
| Neoplasms, Second Primary | 1 | 2012 | 77 | 0.410 |
Why?
| Social Media | 3 | 2018 | 105 | 0.400 |
Why?
| Dermis | 2 | 2021 | 20 | 0.400 |
Why?
| Cesarean Section | 1 | 2012 | 179 | 0.390 |
Why?
| Vulva | 2 | 2020 | 18 | 0.390 |
Why?
| Histones | 3 | 2020 | 335 | 0.380 |
Why?
| Mucous Membrane | 2 | 2020 | 33 | 0.380 |
Why?
| Muir-Torre Syndrome | 1 | 2010 | 1 | 0.370 |
Why?
| Hippocampus | 3 | 2006 | 242 | 0.360 |
Why?
| Gene Rearrangement | 2 | 2021 | 76 | 0.350 |
Why?
| Adolescent | 7 | 2022 | 6897 | 0.330 |
Why?
| Epithelioid Cells | 2 | 2020 | 15 | 0.320 |
Why?
| Up-Regulation | 3 | 2020 | 508 | 0.310 |
Why?
| Mutation | 4 | 2024 | 1501 | 0.300 |
Why?
| Dermatomycoses | 2 | 2016 | 24 | 0.290 |
Why?
| Factor XIIIa | 2 | 2016 | 10 | 0.290 |
Why?
| Leukemia, Myeloid, Acute | 3 | 2016 | 191 | 0.280 |
Why?
| Mutation, Missense | 3 | 2020 | 117 | 0.280 |
Why?
| Neuronal Plasticity | 1 | 2006 | 58 | 0.280 |
Why?
| MAP Kinase Signaling System | 1 | 2006 | 133 | 0.270 |
Why?
| Memory | 1 | 2006 | 124 | 0.270 |
Why?
| Memory Disorders | 1 | 2006 | 62 | 0.270 |
Why?
| Antifungal Agents | 3 | 2016 | 363 | 0.260 |
Why?
| Postoperative Complications | 1 | 2012 | 1033 | 0.260 |
Why?
| Signal Transduction | 2 | 2016 | 1753 | 0.250 |
Why?
| SOXE Transcription Factors | 2 | 2021 | 4 | 0.250 |
Why?
| MART-1 Antigen | 2 | 2021 | 12 | 0.240 |
Why?
| Hematopoietic Stem Cell Transplantation | 3 | 2019 | 573 | 0.240 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 55 | 0.240 |
Why?
| Nevus | 1 | 2024 | 17 | 0.240 |
Why?
| Neurons | 2 | 2006 | 486 | 0.240 |
Why?
| Fear | 1 | 2004 | 87 | 0.230 |
Why?
| Oxalates | 1 | 2022 | 15 | 0.220 |
Why?
| Angioedema | 1 | 2022 | 9 | 0.220 |
Why?
| Demography | 1 | 2022 | 99 | 0.220 |
Why?
| Sarcoidosis | 1 | 2022 | 44 | 0.210 |
Why?
| Rhabdomyosarcoma, Alveolar | 1 | 2022 | 9 | 0.210 |
Why?
| Prednisone | 1 | 2022 | 111 | 0.210 |
Why?
| Plant Structures | 1 | 2021 | 5 | 0.210 |
Why?
| Cotton Fiber | 1 | 2021 | 7 | 0.210 |
Why?
| Foot | 1 | 2022 | 50 | 0.210 |
Why?
| Paper | 1 | 2021 | 16 | 0.210 |
Why?
| Herpesvirus 2, Human | 1 | 2021 | 5 | 0.210 |
Why?
| Lymphokines | 1 | 2021 | 20 | 0.210 |
Why?
| Herpesvirus 1, Human | 1 | 2021 | 15 | 0.210 |
Why?
| Platelet-Derived Growth Factor | 1 | 2021 | 23 | 0.210 |
Why?
| Histocytochemistry | 1 | 2021 | 46 | 0.210 |
Why?
| Dermatofibrosarcoma | 1 | 2021 | 9 | 0.210 |
Why?
| Herpesvirus 3, Human | 1 | 2021 | 28 | 0.200 |
Why?
| Hyperplasia | 1 | 2021 | 107 | 0.200 |
Why?
| Sutures | 1 | 2021 | 45 | 0.200 |
Why?
| Coloring Agents | 1 | 2021 | 84 | 0.200 |
Why?
| Stromal Cells | 1 | 2021 | 79 | 0.200 |
Why?
| Chromones | 1 | 2021 | 16 | 0.200 |
Why?
| Protein Processing, Post-Translational | 2 | 2020 | 183 | 0.200 |
Why?
| Cadherins | 2 | 2019 | 72 | 0.200 |
Why?
| Lost to Follow-Up | 1 | 2020 | 11 | 0.200 |
Why?
| Oncogene Fusion | 1 | 2020 | 4 | 0.200 |
Why?
| Research Report | 1 | 2020 | 16 | 0.190 |
Why?
| DNA-Activated Protein Kinase | 1 | 2021 | 23 | 0.190 |
Why?
| Leprosy, Multibacillary | 1 | 2020 | 5 | 0.190 |
Why?
| Armadillos | 1 | 2020 | 6 | 0.190 |
Why?
| Morpholines | 1 | 2021 | 64 | 0.190 |
Why?
| Skin Transplantation | 1 | 2021 | 50 | 0.190 |
Why?
| S100 Proteins | 2 | 2021 | 41 | 0.190 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 866 | 0.190 |
Why?
| Animals | 10 | 2021 | 14385 | 0.190 |
Why?
| Histiocytes | 1 | 2020 | 12 | 0.190 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2021 | 99 | 0.190 |
Why?
| Neoplasms, Fibrous Tissue | 1 | 2020 | 2 | 0.190 |
Why?
| Germ Cells | 1 | 2020 | 14 | 0.190 |
Why?
| Phagocytosis | 1 | 2020 | 51 | 0.190 |
Why?
| Single-Cell Analysis | 1 | 2020 | 56 | 0.190 |
Why?
| Papillomaviridae | 1 | 2020 | 107 | 0.190 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 74 | 0.190 |
Why?
| Graft Survival | 1 | 2021 | 165 | 0.190 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2020 | 64 | 0.190 |
Why?
| Li-Fraumeni Syndrome | 1 | 2020 | 13 | 0.180 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2020 | 93 | 0.180 |
Why?
| Graft Rejection | 1 | 2021 | 161 | 0.180 |
Why?
| Immunotherapy | 2 | 2019 | 263 | 0.180 |
Why?
| Consensus | 1 | 2020 | 157 | 0.180 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2017 | 90 | 0.180 |
Why?
| Adenocarcinoma | 1 | 2024 | 428 | 0.180 |
Why?
| Elastin | 1 | 2019 | 22 | 0.180 |
Why?
| Intracranial Arteriovenous Malformations | 1 | 2019 | 28 | 0.170 |
Why?
| Integrin alpha Chains | 1 | 2019 | 10 | 0.170 |
Why?
| Cell Cycle Checkpoints | 1 | 2019 | 35 | 0.170 |
Why?
| Disease Progression | 3 | 2020 | 913 | 0.170 |
Why?
| Melanoma, Experimental | 1 | 2019 | 49 | 0.160 |
Why?
| Arteriovenous Malformations | 1 | 2019 | 66 | 0.160 |
Why?
| Child | 4 | 2022 | 7341 | 0.160 |
Why?
| Cricoid Cartilage | 1 | 2017 | 9 | 0.160 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 462 | 0.160 |
Why?
| Collagen | 1 | 2019 | 223 | 0.160 |
Why?
| Acute Disease | 1 | 2019 | 403 | 0.160 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 35 | 0.160 |
Why?
| Neoplasm Staging | 1 | 2020 | 806 | 0.160 |
Why?
| Dilatation | 1 | 2017 | 27 | 0.160 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2018 | 85 | 0.150 |
Why?
| Antigens, CD | 1 | 2019 | 242 | 0.150 |
Why?
| Connective Tissue Diseases | 1 | 2017 | 15 | 0.150 |
Why?
| Tumor Burden | 1 | 2017 | 142 | 0.150 |
Why?
| Parvoviridae Infections | 1 | 2017 | 20 | 0.150 |
Why?
| Parvovirus B19, Human | 1 | 2017 | 17 | 0.150 |
Why?
| Tumor Escape | 1 | 2017 | 21 | 0.150 |
Why?
| Immunologic Surveillance | 1 | 2017 | 14 | 0.150 |
Why?
| CTLA-4 Antigen | 1 | 2017 | 29 | 0.150 |
Why?
| Trachea | 1 | 2017 | 51 | 0.150 |
Why?
| Histone Code | 1 | 2017 | 32 | 0.150 |
Why?
| Practice Guidelines as Topic | 1 | 2020 | 492 | 0.150 |
Why?
| Rhizopus | 1 | 2016 | 6 | 0.150 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2017 | 40 | 0.150 |
Why?
| Sarcoma | 1 | 2018 | 73 | 0.150 |
Why?
| Connexins | 1 | 2016 | 29 | 0.150 |
Why?
| Splenomegaly | 1 | 2016 | 16 | 0.150 |
Why?
| Mucormycosis | 1 | 2016 | 28 | 0.150 |
Why?
| RNA, Fungal | 1 | 2016 | 30 | 0.150 |
Why?
| Ascomycota | 1 | 2016 | 11 | 0.150 |
Why?
| Angiomyoma | 1 | 2016 | 5 | 0.150 |
Why?
| Osteosarcoma | 1 | 2016 | 37 | 0.140 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2016 | 74 | 0.140 |
Why?
| Infant | 2 | 2015 | 3817 | 0.140 |
Why?
| Recurrence | 2 | 2015 | 690 | 0.140 |
Why?
| Human Growth Hormone | 1 | 2016 | 51 | 0.140 |
Why?
| Alopecia | 1 | 2016 | 59 | 0.140 |
Why?
| Candidiasis | 1 | 2016 | 122 | 0.130 |
Why?
| Mice | 6 | 2021 | 6413 | 0.130 |
Why?
| Education, Medical, Continuing | 1 | 2016 | 80 | 0.130 |
Why?
| Dendritic Cells | 1 | 2016 | 142 | 0.130 |
Why?
| Apoptosis | 3 | 2019 | 1300 | 0.130 |
Why?
| Cell Transformation, Neoplastic | 1 | 2016 | 200 | 0.130 |
Why?
| Adipocytes | 1 | 2016 | 129 | 0.130 |
Why?
| Avoidance Learning | 2 | 2006 | 18 | 0.130 |
Why?
| Lung Neoplasms | 2 | 2019 | 642 | 0.130 |
Why?
| Hamartoma Syndrome, Multiple | 1 | 2015 | 16 | 0.130 |
Why?
| Fibrin | 1 | 2015 | 14 | 0.130 |
Why?
| Vasculitis | 1 | 2015 | 30 | 0.130 |
Why?
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 18 | 0.130 |
Why?
| WT1 Proteins | 1 | 2014 | 5 | 0.130 |
Why?
| Facial Neoplasms | 1 | 2015 | 23 | 0.130 |
Why?
| Osteomyelitis | 1 | 2016 | 122 | 0.130 |
Why?
| Carcinosarcoma | 1 | 2015 | 18 | 0.130 |
Why?
| Pigmentation Disorders | 1 | 2014 | 8 | 0.130 |
Why?
| Lysine | 1 | 2015 | 102 | 0.130 |
Why?
| Keratin-20 | 1 | 2014 | 7 | 0.130 |
Why?
| Purpura | 1 | 2014 | 8 | 0.130 |
Why?
| Drug Resistance, Neoplasm | 1 | 2017 | 309 | 0.130 |
Why?
| Hemangiosarcoma | 1 | 2014 | 18 | 0.130 |
Why?
| Herpes Zoster | 1 | 2014 | 15 | 0.130 |
Why?
| Eosinophils | 1 | 2015 | 36 | 0.130 |
Why?
| Fellowships and Scholarships | 1 | 2016 | 117 | 0.130 |
Why?
| Patient Education as Topic | 1 | 2018 | 313 | 0.130 |
Why?
| Churg-Strauss Syndrome | 1 | 2014 | 3 | 0.130 |
Why?
| Loss of Heterozygosity | 1 | 2015 | 97 | 0.130 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 114 | 0.120 |
Why?
| United States | 2 | 2022 | 5217 | 0.120 |
Why?
| Mass Spectrometry | 1 | 2015 | 313 | 0.120 |
Why?
| Antigens, CD34 | 1 | 2014 | 80 | 0.120 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 141 | 0.120 |
Why?
| Exanthema | 1 | 2014 | 36 | 0.120 |
Why?
| Prospective Studies | 1 | 2020 | 2604 | 0.120 |
Why?
| Lymphocytes | 1 | 2015 | 168 | 0.120 |
Why?
| Neutrophils | 1 | 2015 | 154 | 0.120 |
Why?
| Eosinophilia | 1 | 2014 | 39 | 0.120 |
Why?
| Sarcoma, Kaposi | 1 | 2014 | 72 | 0.120 |
Why?
| Neoplasm Proteins | 1 | 2016 | 359 | 0.120 |
Why?
| Membrane Glycoproteins | 1 | 2014 | 269 | 0.110 |
Why?
| Chromosome Aberrations | 1 | 2015 | 316 | 0.110 |
Why?
| Kaplan-Meier Estimate | 3 | 2020 | 514 | 0.110 |
Why?
| Head and Neck Neoplasms | 1 | 2016 | 335 | 0.110 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2013 | 131 | 0.110 |
Why?
| DNA Mismatch Repair | 1 | 2012 | 17 | 0.110 |
Why?
| Prognosis | 4 | 2019 | 2118 | 0.110 |
Why?
| Antibodies, Monoclonal | 1 | 2017 | 562 | 0.110 |
Why?
| Cell Differentiation | 1 | 2014 | 720 | 0.100 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1048 | 0.100 |
Why?
| Treatment Outcome | 5 | 2021 | 5604 | 0.100 |
Why?
| Multiple Myeloma | 2 | 2016 | 3035 | 0.100 |
Why?
| Asthma | 1 | 2014 | 293 | 0.090 |
Why?
| Retrospective Studies | 3 | 2021 | 6432 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 673 | 0.090 |
Why?
| Fatal Outcome | 2 | 2022 | 225 | 0.080 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2019 | 116 | 0.080 |
Why?
| Phorbol Esters | 1 | 2006 | 4 | 0.070 |
Why?
| Association Learning | 1 | 2006 | 13 | 0.070 |
Why?
| Theta Rhythm | 1 | 2006 | 12 | 0.070 |
Why?
| Mice, Mutant Strains | 1 | 2006 | 84 | 0.070 |
Why?
| Isoproterenol | 1 | 2006 | 52 | 0.070 |
Why?
| Adrenergic beta-Agonists | 1 | 2006 | 43 | 0.070 |
Why?
| Amphotericin B | 2 | 2016 | 122 | 0.070 |
Why?
| Maze Learning | 1 | 2006 | 55 | 0.070 |
Why?
| Protein Kinase C | 1 | 2006 | 65 | 0.070 |
Why?
| Child, Preschool | 1 | 2015 | 4147 | 0.070 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 101 | 0.070 |
Why?
| Immunocompromised Host | 2 | 2016 | 130 | 0.070 |
Why?
| Neoplasm Metastasis | 2 | 2016 | 252 | 0.070 |
Why?
| Cell Proliferation | 2 | 2019 | 1096 | 0.060 |
Why?
| T-Lymphocytes | 2 | 2017 | 373 | 0.060 |
Why?
| Superior Cervical Ganglion | 1 | 2004 | 7 | 0.060 |
Why?
| Blotting, Southern | 1 | 2004 | 40 | 0.060 |
Why?
| Sensory Thresholds | 1 | 2004 | 20 | 0.060 |
Why?
| Nerve Growth Factor | 1 | 2004 | 17 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 55 | 0.060 |
Why?
| Intellectual Disability | 1 | 2006 | 149 | 0.060 |
Why?
| Exploratory Behavior | 1 | 2004 | 39 | 0.060 |
Why?
| Luminescent Proteins | 1 | 2004 | 66 | 0.060 |
Why?
| Green Fluorescent Proteins | 1 | 2004 | 110 | 0.060 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 69 | 0.060 |
Why?
| Shock | 1 | 2004 | 37 | 0.060 |
Why?
| Time Factors | 2 | 2016 | 3213 | 0.060 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2004 | 169 | 0.060 |
Why?
| Psychomotor Performance | 1 | 2004 | 156 | 0.060 |
Why?
| Brain | 2 | 2019 | 1387 | 0.060 |
Why?
| Animals, Newborn | 1 | 2004 | 396 | 0.050 |
Why?
| Eyelids | 1 | 2022 | 33 | 0.050 |
Why?
| Behavior, Animal | 1 | 2004 | 200 | 0.050 |
Why?
| Motor Activity | 1 | 2004 | 247 | 0.050 |
Why?
| Blotting, Western | 1 | 2004 | 683 | 0.050 |
Why?
| Desmin | 1 | 2022 | 9 | 0.050 |
Why?
| Edema | 1 | 2022 | 74 | 0.050 |
Why?
| Mice, Transgenic | 1 | 2004 | 656 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2020 | 2387 | 0.050 |
Why?
| gp100 Melanoma Antigen | 1 | 2021 | 9 | 0.050 |
Why?
| Microphthalmia-Associated Transcription Factor | 1 | 2021 | 4 | 0.050 |
Why?
| Gene Expression | 1 | 2004 | 664 | 0.050 |
Why?
| Mycobacterium leprae | 1 | 2020 | 7 | 0.050 |
Why?
| DNA, Viral | 1 | 2021 | 142 | 0.050 |
Why?
| Soil Microbiology | 1 | 2020 | 23 | 0.050 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2021 | 278 | 0.050 |
Why?
| Retinoblastoma Protein | 1 | 2020 | 21 | 0.050 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 17 | 0.050 |
Why?
| Societies, Medical | 1 | 2021 | 194 | 0.050 |
Why?
| Ulcer | 1 | 2020 | 23 | 0.050 |
Why?
| RNA, Messenger | 1 | 2004 | 1202 | 0.050 |
Why?
| Radiotherapy, Adjuvant | 1 | 2020 | 66 | 0.050 |
Why?
| Mice, Inbred BALB C | 1 | 2021 | 368 | 0.050 |
Why?
| Evidence-Based Medicine | 1 | 2021 | 281 | 0.050 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 143 | 0.050 |
Why?
| Antiviral Agents | 1 | 2021 | 188 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 1 | 2004 | 1476 | 0.050 |
Why?
| Germ-Line Mutation | 1 | 2020 | 68 | 0.050 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 62 | 0.050 |
Why?
| Cells, Cultured | 1 | 2004 | 1737 | 0.050 |
Why?
| Rats, Sprague-Dawley | 1 | 2004 | 1663 | 0.050 |
Why?
| Malpractice | 1 | 2019 | 16 | 0.040 |
Why?
| Linear Models | 1 | 2020 | 309 | 0.040 |
Why?
| Microcirculation | 1 | 2019 | 89 | 0.040 |
Why?
| Diagnostic Errors | 1 | 2019 | 74 | 0.040 |
Why?
| Proportional Hazards Models | 1 | 2020 | 431 | 0.040 |
Why?
| Fibrosis | 1 | 2019 | 208 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2020 | 643 | 0.040 |
Why?
| Survival Analysis | 1 | 2020 | 735 | 0.040 |
Why?
| Tumor Cells, Cultured | 1 | 2019 | 477 | 0.040 |
Why?
| Flow Cytometry | 1 | 2021 | 546 | 0.040 |
Why?
| Transcriptome | 1 | 2020 | 346 | 0.040 |
Why?
| Rare Diseases | 1 | 2018 | 46 | 0.040 |
Why?
| Tumor Microenvironment | 1 | 2019 | 209 | 0.040 |
Why?
| Larynx | 1 | 2017 | 39 | 0.040 |
Why?
| Pressure | 1 | 2017 | 120 | 0.040 |
Why?
| Cadaver | 1 | 2017 | 113 | 0.040 |
Why?
| Rats | 1 | 2004 | 3415 | 0.040 |
Why?
| Immunomodulation | 1 | 2017 | 42 | 0.040 |
Why?
| Forkhead Transcription Factors | 1 | 2018 | 118 | 0.040 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2017 | 53 | 0.040 |
Why?
| Forearm | 1 | 2016 | 41 | 0.040 |
Why?
| Debridement | 1 | 2016 | 54 | 0.040 |
Why?
| Induction Chemotherapy | 1 | 2016 | 59 | 0.040 |
Why?
| Blood Cell Count | 1 | 2016 | 43 | 0.040 |
Why?
| Toes | 1 | 2016 | 19 | 0.040 |
Why?
| Disease-Free Survival | 1 | 2017 | 485 | 0.040 |
Why?
| Sebaceous Glands | 1 | 2016 | 12 | 0.040 |
Why?
| Lymphocyte Activation | 1 | 2017 | 197 | 0.040 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 570 | 0.040 |
Why?
| Treatment Refusal | 1 | 2016 | 41 | 0.040 |
Why?
| Chemotherapy, Adjuvant | 1 | 2016 | 119 | 0.040 |
Why?
| Family | 1 | 2018 | 193 | 0.040 |
Why?
| Abscess | 1 | 2016 | 42 | 0.040 |
Why?
| Antibiotic Prophylaxis | 1 | 2016 | 67 | 0.040 |
Why?
| Pilot Projects | 1 | 2019 | 808 | 0.040 |
Why?
| Triazoles | 1 | 2016 | 120 | 0.030 |
Why?
| Cell Movement | 1 | 2017 | 271 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 206 | 0.030 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 48 | 0.030 |
Why?
| Epigenomics | 1 | 2016 | 67 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2016 | 195 | 0.030 |
Why?
| Methylation | 1 | 2015 | 130 | 0.030 |
Why?
| Proteome | 1 | 2017 | 178 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 1999 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2016 | 531 | 0.030 |
Why?
| Disease Models, Animal | 1 | 2021 | 1639 | 0.030 |
Why?
| Comparative Genomic Hybridization | 1 | 2015 | 50 | 0.030 |
Why?
| Pedigree | 1 | 2015 | 146 | 0.030 |
Why?
| Transplantation, Autologous | 1 | 2016 | 476 | 0.030 |
Why?
| Scalp | 1 | 2015 | 53 | 0.030 |
Why?
| Hyperlipidemias | 1 | 2014 | 51 | 0.030 |
Why?
| Reoperation | 1 | 2016 | 454 | 0.030 |
Why?
| Arkansas | 1 | 2020 | 2100 | 0.030 |
Why?
| Respiratory Function Tests | 1 | 2014 | 98 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2015 | 217 | 0.030 |
Why?
| Bone Marrow | 1 | 2016 | 411 | 0.030 |
Why?
| Sensitivity and Specificity | 1 | 2016 | 923 | 0.030 |
Why?
| Lipodystrophy | 1 | 2013 | 10 | 0.030 |
Why?
| Heterozygote | 1 | 2013 | 96 | 0.030 |
Why?
| Incidence | 1 | 2016 | 1082 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2013 | 73 | 0.030 |
Why?
| Syndrome | 1 | 2013 | 252 | 0.030 |
Why?
| Neoplasm Recurrence, Local | 1 | 2016 | 644 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2015 | 399 | 0.030 |
Why?
| Risk Assessment | 1 | 2016 | 1361 | 0.030 |
Why?
| Cell Line, Tumor | 1 | 2015 | 1550 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2014 | 1084 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2016 | 1604 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 1213 | 0.020 |
Why?
| Antineoplastic Agents | 1 | 2016 | 1300 | 0.020 |
Why?
|
|
Shalin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|